Litcius/Paper detail

A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population

David Heredia, Luís Más, Andrés F. Cardona, Víctor Oyervides, Rodrigo Motta, Marco Gálvez-Niño, Luis Lara‐Mejía, Carlos Aliaga-Macha, Carlos Carracedo, Edgar Varela‐Santoyo, Maritza Ramos-Ramírez, David Davila-Dupont, Juan Andrade Martinez, Graciela Cruz‐Rico, Jordi Remón, Óscar Arrieta

2022Lung Cancer15 citationsDOI

Topics & Concepts

AfatinibMedicineGefitinibOsimertinibPTENErlotinibOncologyLung cancerInternal medicineAdenocarcinomaCancerPopulationMutationCancer researchBioinformaticsEpidermal growth factor receptorGeneGeneticsPI3K/AKT/mTOR pathwayBiologyEnvironmental healthApoptosisLung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment
A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population | Litcius